TransMedics Group Inc (TMDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TransMedics Group Inc (TMDX) has a cash flow conversion efficiency ratio of 0.081x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($41.84 Million) by net assets ($518.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TransMedics Group Inc stock valuation for the company's overall valuation and market capitalisation.
TransMedics Group Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how TransMedics Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TransMedics Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TransMedics Group Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of TransMedics Group Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
West African Resources Ltd
AU:WAF
|
0.055x |
|
Natura &Co Holding S.A.
SA:NTCO3
|
-0.072x |
|
Fujian Newland Computer Co Ltd
SHE:000997
|
-0.027x |
|
Shanghai Moons' Elec Co Ltd
SHG:603728
|
0.020x |
|
Betta Pharmaceuticals Co Ltd
SHE:300558
|
0.033x |
|
Shareate Tools Ltd
SHG:688257
|
0.038x |
|
Foxconn Technology Co Ltd
TW:2354
|
0.045x |
|
Beijing Sinnet Technology Co Ltd
SHE:300383
|
0.033x |
Annual Cash Flow Conversion Efficiency for TransMedics Group Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of TransMedics Group Inc from 2006 to 2025. View current stock price of TransMedics Group Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $473.10 Million | $192.84 Million | 0.408x | +90.93% |
| 2024-12-31 | $228.60 Million | $48.80 Million | 0.213x | +324.83% |
| 2023-12-31 | $137.20 Million | $-13.03 Million | -0.095x | +61.17% |
| 2022-12-31 | $187.38 Million | $-45.82 Million | -0.245x | +42.52% |
| 2021-12-31 | $67.85 Million | $-28.86 Million | -0.425x | -46.02% |
| 2020-12-31 | $103.89 Million | $-30.27 Million | -0.291x | +50.69% |
| 2019-12-31 | $54.65 Million | $-32.29 Million | -0.591x | -110.97% |
| 2018-12-31 | $-4.83 Million | $-25.98 Million | 5.385x | +3833.79% |
| 2017-12-31 | $-168.72 Million | $-23.10 Million | 0.137x | +122.03% |
| 2016-12-31 | $38.79 Million | $-24.11 Million | -0.622x | +66.36% |
| 2006-12-31 | $8.80 Million | $-16.27 Million | -1.847x | -- |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more